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Abstract. Extended pulmonary metastasectomy has become 
feasible in patients with extrapulmonary metastases and 
multiple or bilateral pulmonary metastases. Even perito‑
neal dissemination is considered to be curable in modern 
medicine. Therefore, it is necessary to analyze the prognosis 
of patients undergoing complete pulmonary metastasectomy. 
A total of 80 patients who underwent pulmonary resection 
for lung metastases were retrospectively analyzed. The 
eligibility criteria for the present study were as follows: i) the 
primary tumor was controlled; ii) if extrapulmonary metas‑
tases (including peritoneal dissemination) existed, these were 
controlled by local treatment or such treatment was planned; 
iii) the one to three months follow‑up computed tomog‑
raphy (CT) following the first assessment revealed no increase 
of pulmonary metastatic disease; iv) pulmonary metastases 
could be resected completely. The overall 5‑ and 10‑year 
survival rates were 71.7 and 41.5%, respectively. Applying the 
extended criteria for surgery, the present study demonstrated 
that pulmonary metastasectomy resulted in a good patient 
prognosis.
Introduction
Despite the developments in the chemo‑ and radiotherapy, and 
treatment with biological agents of patients with pulmonary 
metastases, surgery is still an important option in this situa‑
tion. Thomford et al (1), presented the criteria for pulmonary 
metastasectomy, which included adequate cardiopulmonary 
reserves of the patient, the control of the primary tumor site, 
no evidence of metastatic disease elsewhere in the body and 
that the pulmonary metastases being limited to one lung. 
However, these criteria have been continuously extended and 
modified over time. Today, extended pulmonary metastasec‑
tomy has become feasible in patients with distant metastases 
such as a solitary liver metastasis or multiple and bilateral 
pulmonary metastases. Therefore, it is time to analyze the 
survival of patients undergoing extended pulmonary metas‑
tasectomy.
Peritoneal dissemination originating from gastrointestinal 
tract organs, pseudomyxoma peritonei, or ovarian cancer has 
for long been considered as a lethal disease with poor prognosis. 
Recently, however, new treatment methods have emerged, 
and nowadays even cure can be achieved with cytoreductive 
surgery and hyperthermic intraperitoneal chemotherapy in 
these patients (2). Consequently, we also need to analyze the 
prognosis of patients with peritoneal dissemination controlled 
by the treatments.
The purpose of this study was to analyze the current data 
for overall survival after extended pulmonary metastasectomy, 
including in patients with treated peritoneal dissemination 
at our institution and to clarify whether above described 
prognostic factors affect survival.
Patients and methods
We obtained institutional review board approval for this study 
(approval no. 2019‑015). The requirement for informed patient 
consent was waived because of the retrospective nature of the 
study.
The present study was a retrospective analysis of the 
medical records of 80 patients who underwent complete resec‑
tion for lung metastases at our hospital between September 
2007 and February 2019. The record of each patient was 
reviewed for age, sex, primary tumor, disease‑free interval, 
number of pulmonary nodules, side of pulmonary nodules, 
extrapulmonary metastases, the maximum diameter of the 
pulmonary nodules, peritoneal dissemination of the primary 
tumor and surgical procedure for metastasectomy. In case 
multiple metastases were present, the diameter of the largest 
nodule was recorded.
The eligibility criteria for this study were as follows:  i) 
the primary tumor was controlled; ii) if extrapulmonary 
metastases (including peritoneal dissemination) existed, these 
had been controlled by local treatment or such treatment was 
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planned; iii) the one to three months follow‑up computed 
tomography (CT) after the first assessment revealed no 
increase of pulmonary metastatic disease and iv) pulmonary 
metastases could be resected completely.
We excluded patients whose performance status was 
over 2, or whose forced expiratory volume in one second 
during the preoperative pulmonary function test was lower 
than 1,000 ml. We included any types of primary tumors 
and did not exclude patients with multiple or bilateral 
pulmonary metastases. All patients with peritoneal dissemi‑
nation received cytoreductive surgery and hyperthermic 
intraperitoneal chemotherapy prior to pulmonary resec‑
tion of metastases. We judged extrapulmonary metastases 
as ‘controlled’ when one to six months follow‑up imaging 
examinations revealed no evidence of relapse after local 
treatment. If a more effective treatment modality than surgery 
was available, the patients received the optimal treatment.
Our standard surgical method includes the complete 
resection of nodules after palpation, while mediastinal lymph 
node dissection is not routinely performed. The surgical 
approach is performed by thoracoscopically assisted or 
lateral thoracotomy. We usually attempt to remove pulmonary 
nodules through a wedge resection whereas hilar nodules 
require lobectomy or pneumonectomy. We defined ‘complete 
resection’ as no obvious residual cancer on the resection stump 
of the lung. Patients are followed‑up for up to 10 years after 
metastasectomy.
Statistical analysis was performed using SPSS Statistics 
for Windows, v22 (SPSS Inc.). The Kaplan‑Meier method was 
used to determine overall, relapse‑free, and median survival 
from the time of metastasectomy to the last follow‑up, death or 
relapse. The log‑rank test was used to compare survival differ‑
ences for each variable. P<0.05 was considered to indicate a 
statistically significant difference.
Results
During the study period, 80 patients underwent pulmonary 
resection for lung metastases in our hospital. We extracted the 
data of these 80 patients. Their clinical, tumor and surgical 
characteristics are shown in Table I. The mean age at the 
time of thoracic surgery was 63.1 years, range 29‑84 years. 
There were 46 male and 34 female patients. The mean period 
between primary tumor surgery and pulmonary resection 
was 39.7 months. The primary tumor was colorectal cancer 
in 43 patients, pseudomyxoma peritonei in 9 patients, head 
and neck cancer in 8 patients and other cancers in 20 patients. 
Twenty‑two patients were treated for peritoneal dissemination 
and were recurrence‑free based on computed tomography or 
magnetic resonance imaging during a follow‑up of at least 
eight months after the intervention. The primary tumor of 
peritoneal dissemination was colorectal cancer in 11 patients, 
pseudomyxoma peritonei in 9 patients and uterine leiomyo‑
sarcoma in 2 patients. Fifty‑five patients received wedge 
resection, 13 patients received segmentectomy, 10 patients 
received lobectomy, and 2 patients received pneumonectomy. 
Post‑operative complications occurred in 13 patients (16.3%), 
which consisted of pneumonia in 3 patients, empyema in 
3 patients, intrathoracic bleeding in 1 patient, gastrointestinal 
bleeding in 1 patient, respiratory failure requiring oxygen 
inhalation in 1 patient, heart failure in 1 patient, ileus in 
1 patient, deterioration in liver function in 1 patient and 
recurrent nerve paralysis in 1 patient.
The mean follow‑up after thoracic surgery was 36 months, 
range 1‑120 months. The 5‑year and 10‑year survival rates after 
metastasectomy were 71.7 and 41.5%, respectively (Fig. 1). 
Relapse‑free survival at five years after metastasectomy was 
33.6% (Fig. 1) and median survival time 84.7 months.
We compared the median survival times with the clinical 
factors of age, gender, primary tumor, disease‑free interval, 
number of pulmonary metastases, laterality of the metastases, 
maximum tumor size, extrapulmonary metastases, and 
peritoneal dissemination. In the univariate analysis, none of 
these factors showed a significant association with the median 
survival time (Table II). However, bilateral metastases, 
extrapulmonary metastases, treated peritoneal dissemination, 
Table I. Characteristics of 80 patients undergoing pulmonary 
resection for lung metastases.
 Number of patients 
Characteristics n=80 %
Age (years) 63.1 (29‑84) ‑
Sex  
  Male 46 58
  Female 34 42
Primary tumor  
  Colorectal 43 54
  Pseudomyxoma peritonei 9 11
  Head and neck cancer 8 10
  Other cancers 20 25
Disease‑free interval (Mo)  26.2 (0‑156) ‑
Pulmonary metastases (No) 1.7 (1‑13) 
  1 58 73
  2 11 14
  ≥3  11  14
Side  
  Unilateral 66 82
  Bilateral 14 18
Extrapulmonary metastasis  
  Yes 13 16
  No 67 84
Maximum tumor size 20.8 (7‑146) 
  ≤20 mm  55  69
  >20 mm 25 31
Peritoneal dissemination  
  Yes 22 28
  No 58 72
Surgical procedure  
  Wedge resection 55 69
  Segmentectomy 13 16
  Lobectomy 10 13
  Pneumonectomy 2   3
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and histology of pseudomyxoma peritonei tended to be 
associated with lower survival (Fig. 2).
There was no significant difference (P=0.059) in the 5‑year 
survival of patients with peritoneal dissemination (55.8%) 
and patients without history of peritoneal dissemination 
(76.4%) (Fig. 3).
Discussion
The indication for pulmonary metastasectomy has been based 
on Thomford's criteria (1) for a long time, but recently, it 
was increasingly extended to patients with multiple lesions, 
bilateral lesions, and solitary liver metastasis. Furthermore, 
the development of cytoreductive surgery and hyperthermic 
intraperitoneal chemotherapy appears to contribute to better 
prospects of cure for patients with peritoneal dissemination (2). 
In this study, we included survival in patients who had been or 
were foreseen to be treated for peritoneal dissemination.
At our institution, the extended criteria for pulmonary 
resection include multiple lesions, extrapulmonary metastases, 
bilateral metastases, and peritoneal dissemination. A previous 
article reported that multiple pulmonary metastases were not 
a prognostic factor for overall survival (3) whereas another 
article reported them to be a significant factor (4). In our 
study, the prognosis of multiple pulmonary metastases was 
no different from a solitary metastasis. Although patients 
with bilateral metastases, extrapulmonary metastases, and 
peritoneal dissemination tended to obtain less benefit from 
surgery, the differences between their mean survival time 
and those of other patients were not statistically significant. 
Several studies have investigated the difference between 
unilateral and bilateral metastases in terms of survival. Only 
two articles reported that unilateral pulmonary metastases 
were a positive prognostic factor for overall survival (3,5). 
There have been several reports about metastasectomy in 
patients with extrapulmonary metastases. McAfee et al (6) and 
Saito et al (7), both showed that the presence of resectable or 
controllable extrapulmonary metastases before or at the time 
of thoracotomy was not associated with decreased survival. 
These results suggest that metastasectomy might be beneficial 
Figure 1. Kaplan‑Meier curves for overall and relapse‑free survival in 80 patients undergoing pulmonary resection for lung metastases.
Figure 2. Median survival time in relation to clinical factors in 80 patients undergoing pulmonary resection for lung metastases. DFI, disease‑free interval.
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when extrapulmonary metastases are controllable, for example, 
in the case of a solitary liver metastasis.
The original aspect of our study was to include patients 
with previously treated peritoneal dissemination. There have 
been no reports on pulmonary metastasectomy in these 
patients. Peritoneal dissemination originating from the 
gastrointestinal organs, pseudomyxoma peritonei or ovarian 
cancer has often been considered as a systemic and lethal 
disease with poor prognosis. As a consequence, supportive 
care and systemic chemotherapy were the main treatment 
strategy for long, even though systemic chemotherapy is 
not sufficient to control peritoneal dissemination. However, 
more recently, specialized hospitals have reported that even 
cure could be achieved by the combination of cytoreductive 
surgery and hyperthermic intraperitoneal chemotherapy, 
with 5‑year survival rates of 45% in colorectal cancer, 10.7% 
in gastric cancer, 58% in ovarian cancer and a 10‑year 
survival rate of 63% in pseudomyxoma peritonei (2) after 
cytoreductive surgery. Furthermore, we showed for the first 
time a 5‑year survival rate of 55.8% and a mean survival time 
of 50.9 months after pulmonary metastasectomy in these 
patients. Considering that there was long period between 
primary tumor surgery and pulmonary metastasectomy 
(39.7 months) in our study, our survival rate after pulmo‑
nary metastasectomy might be sufficiently acceptable. With 
increased survival in patients with peritoneal dissemination, 
the opportunity of pulmonary metastasectomy will also 
increase.
With regard to the different primary tumors, colorectal 
and head and neck cancer achieved a mean survival time of 
81.1 and 94.4 months, respectively, whereas pseudomyxoma 
peritonei showed a poor prognosis. Pseudomyxoma peritonei 
is divided into a low‑grade and high‑grade form. The 5‑year 
overall survival rate was found to be 63% for low grade but 
only 23% for high grade disease after surgical resection (8,9). 
Metastases tend to occur in high‑grade disease, which might 
contribute to the poor prognosis of pulmonary metastases of 
pseudomyxoma peritonei in our study.
The overall 5‑year and 10‑year survival rate in our study 
was 71.7 and 41.5%, respectively, and the mean survival time 
was 84.7 months. Thomford et al reported a 5‑year survival 
rate of 30.3%. Another more recent report in 2012 showed a 
5‑year survival rate of 43.7% and a 10‑year survival rate of 
about 30% (4). Despite our extended criteria for pulmonary 
resection of metastases, we achieved better survival rates. 
The reason for the better survival might be threefold. First, 
the new modes of non‑surgical treatment such as systemic 
chemotherapy, hyperthermic intraperitoneal chemo‑
therapy, biological agents and radiotherapy might prolong 
the overall survival in patients with advanced cancer. 
Second, we excluded all cases with increasing pulmonary 
metastases during one to three months. We hypothesized 
that when metastasic disease increased in the short term, 
systemic chemotherapy was likely to be more effective 
than local treatment such as surgery. Third, we extracted 
data only on cases with complete resection of pulmonary 
Table II. Median survival time in relation to clinical factors 
in 80 patients undergoing pulmonary resection for lung 
metastases.
  Mean 
  survival 
  time 
Variables N (months) P‑value
Age (years)   0.700
  <65 38 84.7 
  ≥65  42  84.1 
Sex   0.379
  Male 46 79.1 
  Female 34 92.5 
Primary tumor   
  Colorectal 43 81.1 0.686
  Pseudomyxoma peritonei   9 41.1 0.296
  Head and neck cancer   8 94.4 0.277
Disease‑free interval (Months)    0.821
  0‑12  30 96.6 
  13‑ 48 83.0 
Pulmonary metastases (No)   0.891
  1 58 84.6 
  ≥2  22  80.0 
Laterality of the metastases   0.124
  Unilateral 66 88.9 
  Bilateral 14 56.4 
Maximum tumor size   0.513
  ≤20 mm  55  87.0 
  >20 mm 25 77.1 
Extrapulmonary metastases   0.261
  Yes 13 52.0 
  No 67 87.3 
Peritoneal dissemination   0.059
  Yes 22 50.9 
  No 58 90.9 
Figure 3. Overall survival after pulmonary metastasectomy in 80 patients 
with cancer with (n=22) and without (n=58) peritoneal dissemination.
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metastases. Predictors of good prognosis usually include 
long disease‑free interval, the histology of the primary 
tumor, a small number of metastases, unilateral metastases, 
and complete resection. Among these, the most consistent 
predictor is complete resection (10).
The main limitation of this study is its retrospective 
nature. The final decision to select a patient for surgery may 
vary among surgeons. Therefore, our study does not reflect 
the entire population of patients with pulmonary metastases. 
A second limitation is the small number of cases. This might 
result in insufficient power to detect significant differences, 
even in cases that potentially might show statistical differ‑
ences. The final limitation is the heterogeneity of the histology 
of the primary tumor. Tumor characteristics such as growth 
speed, metastatic potential, and anticancer drug sensitivity 
differ depending on the histology of the primary lesion. We 
also recognize that non‑surgical treatment such as chemo‑
therapy, thermotherapy, biological agents or radiotherapy 
may substantially affect the prognosis of patients in our study. 
Based on this pilot study, we plan to perform a prospectively 
designed study with sufficiently large patient numbers and 
segregation by histology.
In conclusion, our extended pulmonary metastasectomy 
achieved 5‑year and 10‑year survival rates of 71.7 and 41.5%, 
respectively. Extended criteria in our study including multiple 
lung lesions, bilateral metastases, controlled extrapulmonary 
metastases and controlled peritoneal dissemination might be 
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